Research paves the way for treatment strategies of multidrug-resistant chronic infections
Antibiotic-resistant Pseudomonas infections in cystic fibrosis patients show predictable sensitivities to other classes of antibiotics
Antibiotic-resistant Pseudomonas infections in cystic fibrosis patients show predictable sensitivities to other classes of antibiotics. A new study made by scientists at the Technical University of Denmark suggests that this could lead to new ways of optimizing treatments for chronic infections.
The researchers found some antibiotic vulnerabilities of multidrug-resistant pathogens were preserved across clinical isolates isolated over decades at the Cystic fibrosis clinic at Rigshospitalet in Copenhagen. Interestingly, it thereby became possible to identify the underlying mutations that caused the sensitivity. The researchers explained that targeting vulnerabilities of phenotypic states related to specific mutations could potentially have a huge impact because it makes it possible to make a more personalized treatment strategy for each patient.
The results of the study indicate that for some antibiotics, exposure and subsequent resistance evolution leads to convergence toward specific phenotypes states. Thus, collateral sensitivity may be particularly useful for optimizing treatments of chronic infections since their nature and severity warrants and requires tailored treatment strategies.
The researcher concluded that the study supports the notion that treatment of chronically infected patients could be significantly improved based on specific diagnostic markers that are associated with a collateral sensitivity to specific drugs. The next step is to translate these findings into clinical benefits to patients.
Read more at: http://bit.ly/2m0hKwm
The researchers found some antibiotic vulnerabilities of multidrug-resistant pathogens were preserved across clinical isolates isolated over decades at the Cystic fibrosis clinic at Rigshospitalet in Copenhagen. Interestingly, it thereby became possible to identify the underlying mutations that caused the sensitivity. The researchers explained that targeting vulnerabilities of phenotypic states related to specific mutations could potentially have a huge impact because it makes it possible to make a more personalized treatment strategy for each patient.
The results of the study indicate that for some antibiotics, exposure and subsequent resistance evolution leads to convergence toward specific phenotypes states. Thus, collateral sensitivity may be particularly useful for optimizing treatments of chronic infections since their nature and severity warrants and requires tailored treatment strategies.
The researcher concluded that the study supports the notion that treatment of chronically infected patients could be significantly improved based on specific diagnostic markers that are associated with a collateral sensitivity to specific drugs. The next step is to translate these findings into clinical benefits to patients.
Read more at: http://bit.ly/2m0hKwm
Like
Comment
Share
